Μετάβαση στο περιεχόμενο

ΕτικέταAllergan

Will payers support Amgen’s ‘bolus’ of eager Aimovig patients in time to fend off migraine rivals?

Even though Amgen and Novartis rolled out their hot new migraine drug, Aimovig, at a lower-than-expected price of $6,900, the companies expected pushback from payers, and they prepared for that … Continue Reading Will payers support Amgen’s ‘bolus’ of eager Aimovig patients in time to fend off migraine rivals?